TABLE 1.
Measures | Real (n = 20) | Sham (n = 17) | t/X 2 | p |
---|---|---|---|---|
Mean ± SD | Mean ± SD | |||
Demographic data | ||||
Age (years) | 27.75 ± 1.58 | 27.65 ± 1.73 | .044 a | .763 |
Sex (male/female) | 15/5 | 12/5 | — | >.99 b |
Education (years) | 14.05 ± 0.50 | 12.82 ± 0.516 | 1.700 a | .098 |
Illness duration (years) | 5.81 ± 0.90 | 4.24 ± 0.88 | 1.241 a | .223 |
Medication (yes/no) | 14/6 | 14/3 | — | .462 b |
No. drug types | 1.5 ± 1.40 | 2.2 ± 1.67 | 1.34 | .19 |
Symptom estimations | ||||
Y‐BOCS total (primary outcome) | 21.00 ± 1.13 | 20.29 ± 1.25 | 0.420 a | .677 |
Y‐BOCS obsessive | 11.60 ± 0.87 | 10.94 ± 1.04 | 0.489 a | .628 |
Y‐BOCS compulsive | 9.40 ± 1.01 | 9.35 ± 1.23 | 0.030 a | .976 |
HARS | 8.05 ± 0.75 | 6.35 ± 0.73 | 1.616 a | .115 |
HDRS | 6.85 ± 0.89 | 5.94 ± 0.67 | 0.792 a | .434 |
Neuropsychological tests | ||||
TMT A (second) | 53.57 ± 4.28 | 59.69 ± 5.93 | 0.849 c | .402 |
TMT B (second) | 98.77 ± 4.46 | 114.90 ± 11.18 | 1.393 c | .173 |
SCWT (second) | 10.93 ± 1.53 | 8.75 ± 1.35 | 1.065 d | .295 |
DS forward | 7.79 ± 0.12 | 7.88 ± 0.08 | 0.617 c | .542 |
DS backward | 5.84 ± 0.23 | 6.18 ± 0.27 | 0.935 c | .356 |
Target information c | ||||
MNI coordinate X | 8.33 ± 3.18 | 9.00 ± 2.35 | 0.66 d | .52 |
MNI coordinate Y | 12.33 ± 7.12 | 9.79 ± 7.08 | 1.00 d | .32 |
MNI coordinate Z | 59.50 ± 4.96 | 62.50 ± 4.49 | 1.77 d | .09 |
zFC to STN | 0.11 ± 0.09 | 0.10 ± 0.08 | 0.21 d | .84 |
Abbreviations: DS, Digit Span; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; MNI, Montreal Neurological Institute; SCWT, Stroop Color Word Test; STN, subthalamic nucleus; TMT, Trail Making Test; Y‐BOCS, Yale‐Brown Obsessive Compulsive Scale; zFC, Fisher's z transformed functional connectivity.
Paired t test.
Fisher's exact test.
One patient in the real group did not compete these tests.
The data were from 18 and 14 patients in the real group and sham group, respectively.